NCT01028586View on ClinicalTrials.gov

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)

PHASE3TerminatedINTERVENTIONAL
Enrollment

507

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2012

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

Safinamide, MAO-B inhibitor

Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.

DRUG

Safinamide, MAO-B inhibitor

Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.

DRUG

Placebo

matching placebo tablets

Trial Locations (1)

Unknown

Enquire Central Contact, Geneva

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) | Biotech Hunter | Biotech Hunter